» Articles » PMID: 11923161

Randomised Controlled Trial of Short Bursts of a Potent Topical Corticosteroid Versus Prolonged Use of a Mild Preparation for Children with Mild or Moderate Atopic Eczema

Overview
Journal BMJ
Specialty General Medicine
Date 2002 Mar 30
PMID 11923161
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine whether a three day burst of a potent corticosteroid is more effective than a mild preparation used for seven days in children with mild or moderate atopic eczema.

Design: Randomised, double blind, parallel group study of 18 weeks' duration.

Setting: 13 general practices and a teaching hospital in the Nottingham area.

Participants: 174 children with mild or moderate atopic eczema recruited from general practices and 33 from a hospital outpatient clinic.

Interventions: 0.1% betamethasone valerate applied for three days followed by the base ointment for four days versus 1% hydrocortisone applied for seven days.

Main Outcome Measures: Primary outcomes were total number of scratch-free days and number of relapses. Secondary outcomes were median duration of relapses, number of undisturbed nights, disease severity (six area, six sign atopic dermatitis severity scale), scores on two quality of life measures (children's life quality index and dermatitis family impact questionnaire), and number of patients in whom treatment failed in each arm.

Results: No differences were found between the two groups. This was consistent for all outcomes. The median number of scratch-free days was 118.0 for the mild group and 117.5 for the potent group (difference 0.5, 95% confidence interval -2.0 to 4.0, P=0.53). The median number of relapses for both groups was 1.0. Both groups showed clinically important improvements in disease severity and quality of life compared with baseline.

Conclusion: A short burst of a potent topical corticosteroid is just as effective as prolonged use of a milder preparation for controlling mild or moderate atopic eczema in children.

Citing Articles

Systems Biology Methods via Genome-Wide RNA Sequences to Investigate Pathogenic Mechanisms for Identifying Biomarkers and Constructing a DNN-Based Drug-Target Interaction Model to Predict Potential Molecular Drugs for Treating Atopic Dermatitis.

Chou S, Chuang Y, Chen B Int J Mol Sci. 2024; 25(19).

PMID: 39409019 PMC: 11477013. DOI: 10.3390/ijms251910691.


Topical Treatments in Atopic Dermatitis: An Expansive Review.

Lazar M, Zhang A, Vashi N J Clin Med. 2024; 13(8).

PMID: 38673458 PMC: 11050343. DOI: 10.3390/jcm13082185.


Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of....

Galli E, Belloni Fortina A, Ricci G, Maiello N, Neri I, Baldo E Ital J Pediatr. 2022; 48(1):95.

PMID: 35701810 PMC: 9195338. DOI: 10.1186/s13052-022-01278-7.


Strategies for using topical corticosteroids in children and adults with eczema.

Lax S, Harvey J, Axon E, Howells L, Santer M, Ridd M Cochrane Database Syst Rev. 2022; 3:CD013356.

PMID: 35275399 PMC: 8916090. DOI: 10.1002/14651858.CD013356.pub2.


New Strategies for Improving Budesonide Skin Retention.

Padula C, Machado I, Vigato A, de Araujo D Pharmaceutics. 2022; 14(1).

PMID: 35056927 PMC: 8781796. DOI: 10.3390/pharmaceutics14010030.


References
1.
Emerson R, Williams H, Allen B . Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol. 1998; 139(1):73-6. DOI: 10.1046/j.1365-2133.1998.02316.x. View

2.
Charman C, Morris A, Williams H . Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000; 142(5):931-6. DOI: 10.1046/j.1365-2133.2000.03473.x. View

3.
Berth-Jones J . Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol. 1996; 135 Suppl 48:25-30. DOI: 10.1111/j.1365-2133.1996.tb00706.x. View

4.
Emerson R, Charman C, Williams H . The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland grading. Br J Dermatol. 2000; 142(2):288-97. DOI: 10.1046/j.1365-2133.2000.03300.x. View

5.
Tsukahara K, Takema Y, Moriwaki S, Fujimura T, Imokawa G . Dermal fluid translocation is an important determinant of the diurnal variation in human skin thickness. Br J Dermatol. 2001; 145(4):590-6. DOI: 10.1046/j.1365-2133.2001.04430.x. View